P=N/A, N=440, Active, not recruiting, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Recruiting --> Active, not recruiting

P2, N=20, Recruiting, University of Colorado, Denver | Initiation date: Dec 2025 --> Dec 2026

Here, we employed an integrative biochemical approach combining a novel flux tracing method (using d17dihydrosphingosine) with in situ enzymatic activity assays in the context of treatment with Doxorubicin (Dox), a DNA-damaging agent causing well-established dose-dependent activation of p53...iv) With respect to inhibition of d17sphingomyelin synthesis, an investigation into ceramide transport to the Golgi identified the ceramide transport protein 1 (CERT1) as a novel target of Dox (reduction of protein and activity) and p53 (reduction of activity, particularly at low Dox). These observations underscore p53's prominent role as a master regulator of SPL metabolism, inducing major remodeling of cellular SPL metabolism with extensive and integrated effects on sphingolipid synthesis.

This system is composed of a three-dimensional network formed by dipotassium glycyrrhizinate (DG) and hydroxypropyl methylcellulose (HPMC) for the delivery of levofloxacin (LEV)...Consequently, it effectively inhibited CNV progression, reduced corneal opacity, and promoted corneal repair. This multifunctional smart hydrogel represents a highly promising strategy for the treatment of CNV.

P=N/A, N=70, Not yet recruiting, The First Affiliated Hospital with Nanjing Medical University

These findings suggest that Ag-NPs may enhance upstream signaling and drug response rather than directly acting on apoptotic proteins, supporting their potential as nanotechnological co-therapeutics in B-cell ALL. Further mechanistic and in vivo studies are warranted.

Eighty-three percent of CR-NEC received first-line platinum-etoposide, while 98% of CR-AC patients received first-line fluorouracil-based chemotherapy. Metastatic CR-NEC and CR-AC are clinically distinct, with NEC demonstrating more aggressive features, limited treatment effect, and worse prognosis. Although they share important driver mutations, the underlying reason for their marked clinical differences remains unclear.

The WTAP/TP53BP1 axis impairs periodontal tissue regeneration by promoting P-PDLSC senescence and suppressing osteogenic differentiation in an m6A-dependent manner, revealing a new cellular-level target for treating periodontitis.

The patient initially responded to platinum-etoposide chemotherapy but experienced treatment interruption during the COVID-19 pandemic, followed by recurrent malignant airway obstruction and respiratory failure...Subsequently, chemotherapy combined with the programmed cell death protein-1 (PD-1) inhibitor serplulimab was initiated, followed by maintenance immunotherapy...At five years after initial diagnosis, the patient remains alive with stable disease and without severe treatment-related adverse events. This case highlights the potential role of integrating bronchoscopic local interventions with systemic chemotherapy and immunotherapy to enable durable disease control and long-term survival in selected patients with ES-SCLC complicated by central airway obstruction.

Taken together, our results identify a distinct type of ribosome-enriched SGs that form through RNA-ribosome condensation rather than classical translational stress pathways. This mechanism provides a direct example of how a clinically used drug can reorganize cytoplasmic RNA-protein complexes, with possible consequences for mRNA regulation, cancer therapy, and neurodegenerative disease.

These findings demonstrate that PPA is unlikely to be a substrate of ABCG2 but functionally inhibits ABCG2-mediated efflux, contributing to the restoration of MTX sensitivity, although there may be additional mechanisms involved. PPA could be a promising MDR-reversal agent in ABCG2-driven chemotherapy resistance.

Among them, HB183, HB209, and HB210 exhibited the most potent growth inhibition (GI) activity, with average values of 78.25%, 76.34%, and 79.14%, respectively-surpassing the reference drug doxorubicin (61.89%)...Molecular docking, molecular dynamics simulation (for 500 ns), and MM-GBSA calculations for the lead analogue (HB183) towards the BCL-2 target, as a crucial one in the pathway of apoptosis induction, were performed to support the mechanistic investigation. These findings suggest that HB183 is a promising lead for further development as a selective and potent anticancer agent, particularly in the treatment of breast cancer.